Juvenescence Secures $76M in Series B-1 Funding Led by Abu Dhabi's M42 for Age-Related Disease Therapeutics
• Juvenescence has raised $76 million in the first tranche of its Series B-1 financing round, led by Abu Dhabi's M42, to advance its clinical pipeline targeting age-related diseases.
• The funding is part of a strategic partnership with M42 to establish a drug development hub in Abu Dhabi, combining M42's healthcare data expertise with Juvenescence's AI-enabled discovery technology.
• Juvenescence aims to complete the full financing in Q3 2025, supporting its transition to a clinical-stage biotech company developing novel medicines that target core aging mechanisms.
© Copyright 2025. All Rights Reserved by MedPath